Table 3.

Univariate and multivariate analysis for overall survival.

Variable	Univariate analysis		Multivariate analysis&
	Hazard ratio (CI 95%)	p-value	Hazard ratio (CI 95%)	p-value
WHO 2016 classification
Recurrent genetic abnormalities (ref)
Myelodysplasia-related changes	2.74 (1.29–5.83)	0.009*	2.045 (0.84–5.00)	0.116
Therapy-related	2.58 (1.04–6.37)	0.040*	2.00 (0.67–5.92)	0.213
Not otherwise specified	1.10 (0.43–2.80)	0.838
Blastic phase of MPN Ph−	3.42 (0.73–15.95)	0.12
ELN 2017 risk classification#
Favorable risk(ref)
Intermediate risk	1.68 (0.69–4.07)	0.253*	2.11 (0.72–6.168)	0.173
Adverse risk	2.45 (0.97–6.18)	0.058*	2.29 (0.67–7.83)	0.188
Complex karyotype#
No (ref)
Yes	2.49 (1.46—5.58)	0.002*
Monosomal karyotype
No (ref)
Yes	3.94 (1.91–8.15)	< 0.001*	4.196 (2.02–8.74)	< 0.001*
MRD status by MFC before HSCT
Negative (<0.1%) (ref)
Positive (≥0.1)	1.54 (0.87–2.72)	0.138
Complete remission before HSCT
CR1 (ref)
≥CR2	1.34 (0.67–2.68)	0.411
HCT-CI score at HSCT
<3 (ref)
≥3	1.85 (0.98–3.48)	0.059*	1.14 (0.44–2.94)	0.772
Conditioning intensity
Myeloablative (red)
Reduced intensity	1.86 (1.07–3.23)	0.028*	1.09 (0.52–2.28)	0.826
Age at HSCT
<60 years (ref)
≥60 years	2.01 (1.13–3.59)	0.018*	2.14 (1.13–4.05)	0.019*

*p-value < 0.05; CR1, first complete remission; CR2, second complete remission; ELN, European LeukemiaNet; HCT-CI, hematopoietic cell transplantation–specific comorbidity index. HSCT, hematopoietic stem cell transplantation; MPN Ph−, myeloproliferative neoplasm Philadelphia negative; MRD, minimal residual disease; MFC, multiparameter flow cytometry; NOS, not otherwise specified; WHO, World Health Organization.

&Variables with a p-value < 0.100 and those that are confounding were included.

Variables were not included in the multivariate analysis due to high collinearity with the monosomic karyotype variable.

All values in bold correspond to those marked with an *, as specified in the legend of each table, indicating p < 0.05.